| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
|
Brown, Patrick A.
|
|
|
134 |
S2 |
p. LBA-1
|
artikel
|
| 2 |
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
|
Usmani, Saad Z.
|
|
|
134 |
S2 |
p. LBA-6
|
artikel
|
| 3 |
Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study
|
Röth, Alexander
|
|
|
134 |
S2 |
p. LBA-2
|
artikel
|
| 4 |
Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
Iacobucci, Ilaria
|
|
|
134 |
S2 |
p. LBA-4
|
artikel
|
| 5 |
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
|
Wei, Andrew H.
|
|
|
134 |
S2 |
p. LBA-3
|
artikel
|
| 6 |
Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing
|
Esrick, Erica B.
|
|
|
134 |
S2 |
p. LBA-5
|
artikel
|
Tijdschrift beschrijving